Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Catumaxomab - Lindis Biotech

Next Previous
Drug Profile

Catumaxomab - Lindis Biotech

Alternative Names: Anti-CD3 anti-EpCAM monoclonal antibody; Anti-EpCAM anti-CD3 monoclonal antibody; KORJUNY; LP-000; Removab

Latest Information Update: 19 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lindis Biotech
  • Developer Lindis Biotech; Linton Pharm; Neovii Biotech; Pharmanovia; TRION Pharma
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Gastric cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Malignant ascites
  • Phase III Gastric cancer
  • Phase I/II Bladder cancer
  • Discontinued Carcinoma; Ovarian cancer

Most Recent Events

  • 15 Dec 2025 Launched for Malignant ascites in Germany (Intraperitoneal)
  • 10 Feb 2025 Registered for Malignant ascites in European Union, Iceland, Liechtenstein, Norway (Intraperitoneal) - First global approval
  • 19 Nov 2024 EU marketing authorization is anticipated by the end of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top